LSX Congress | London | Connecting biotech leaders

Biotech Leaders is part of LSX World

For the last 9 years, Biotech Leaders has been working with international life science & healthcare decision makers who are leading the next wave of industry innovation.

Our mission is to help them overcome challenges by connecting them with advisors and strategic partners that can help take their innovation from concept to market.

At the heart of the Biotech Leaders network are the founders and CEOs of the world’s most innovative drug discovery and therapeutic start-ups and SMEs.

They are joined by leading health and life science investors from across Europe and the USA and pharma who are on the look out for new innovation, partners and advisors.

Ryan Richardson

Chief Strategy Officer, BioNTech

Theodora Harold

CEO, Crescendo Biologics

Joern-Peter Halle

Chief Strategy Officer, Merck KGaA

Martine Zimmerman

SVP, Head of Regulatory & Quality Affairs, Alexion/AstraZeneca

Jane Buus Laursen

Corporate VP Business Development, Novo Nordisk

Nauman Shah

Global Head, Janssen Business Development, Johnson & Johnson

Elizabeth Mily

EVP Strategy & Business Development, Bristol Myers Squibb

Beatriz Rodriguez

SVP Talent, Inclusion & Diversity, Bayer

Stephen Squinto

CIO, JP Morgan Life Sciences Private Capital

Monika Vnuk

MD, Blackstone Life Sciences

Linden Thomson

Co-Head, Global Equity, AXA Investment Managers

Jie D’Elia

SVP Business Development, Oncology & Haematology, Bristol Myers Squibb

5 reasons to choose Biotech Leaders

LSX World Biotech Key Reasons 01

Biotech Leaders @ LSX World Congress is Europe’s largest and most significant Biotech CEO gathering. No other event is exclusively designed to address all the strategic and partnering goals of Europe’s Biotech CEO ecosystem.

LSX World Biotech Key Reasons 02

Biotech Leaders @ LSX World Congress attracts the highest quality speakers from the biggest and best large pharma and life science investment firms. Hear from global BD heads at Pfizer, J&J, Merck KGaA, BMS, Novo Nordisk and top tier investment funds like Blackstone, JP Morgan, Sofinnova and Axa.

LSX World Biotech Key Reasons 03

No other event offers access to as many highly-qualified, specialist life science investors. LSX World Congress will be bringing over 350 of the world’s most active investors to London. Fundraising? There’s no better place to be.

LSX World Biotech Key Reasons 04

All biotechs, investors and pharma attendees are qualified during the registration process to ascertain their stage of development, strategic goals, therapeutic preferences, and fundraising/allocation targets. This provides absolute clarity on the issues that matter most to our attendees and allows delegates and partners to identify and target the most qualified prospects through our highly sophisticated 1-2-1 partnering system.

LSX World Biotech Key Reasons 05

As well as partnering, content, showcases and exhibition, Biotech Leaders @ LSX World Congress offers a range of smaller group meetings/CEO forums/workshops targeting particular profiles of attendees. This means highly qualified groups of attendees to meet in an interactive and intimate setting and provides you with the opportunity to talk to the people that matter most to you.